Tibezonium is a new drug that is currently in development for the treatment of a rare disorder called hereditary angioedema (HAE). It is a small molecule that has been designed to block the activity of a protein called plasma kallikrein, which is thought to play a key role in the development of HAE.

Benefits:

• Reduces symptoms of Hereditary Angioedema (HAE): Tibezonium is designed to reduce symptoms of HAE, including swelling of the face, arms, legs, throat, and abdomen.

Side effects:

• There is currently limited information available on the safety and efficacy of Tibezonium as it is still in the development stage.

It’s important to note that Tibezonium is not yet approved by the FDA and is currently in phase 2 clinical trials. Therefore, it’s not available for general use and its benefits and side effects are not fully known yet. It’s essential to consult with a healthcare professional before using Tibezonium or any other new drug that is not FDA approved.